AR053065A1 - Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen - Google Patents

Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen

Info

Publication number
AR053065A1
AR053065A1 ARP060101598A ARP060101598A AR053065A1 AR 053065 A1 AR053065 A1 AR 053065A1 AR P060101598 A ARP060101598 A AR P060101598A AR P060101598 A ARP060101598 A AR P060101598A AR 053065 A1 AR053065 A1 AR 053065A1
Authority
AR
Argentina
Prior art keywords
substituted
group
alkyl
hydrogen
phenyl
Prior art date
Application number
ARP060101598A
Other languages
English (en)
Original Assignee
Sk Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115369&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Corp filed Critical Sk Corp
Publication of AR053065A1 publication Critical patent/AR053065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos azol que contienen grupos carbamoilo y sales utiles para uso farmacéutico de los mismos. Los compuestos son anticonvulsivos efectivos que se utilizan en el tratamiento de trastornos del sistema nervioso central, en especial ansiedad, depresion, convulsion, epilepsia, migrana, trastorno bipolar, abuso, de drogas, hábito de fumar, ADHD, obesidad, trastorno del sueno, apoplejía, dolor neuropático, discapacidad cognitiva, neurodegeneracion y espasmo muscular. Se incluyen composiciones farmacéuticas que los contienen. Reivindicacion 1: Un azol que comprende un compuesto de la formula (1), donde G es un anillo seleccionado del grupo que consiste en piperonilo, indanilo, naftilo, fenilo y fenoximetilo, anillo que puede sustituirse con uno o más sustituyentes idénticos o diferentes seleccionados del grupo que consiste en hidrogeno, alquilo inferior C1-8, halogeno, alcoxi C1-8, tioalcoxi C1-8, hidroxi, perfluoroalquilo, fenoxi, fenilalquiloxi C1-8 o fenoxialquilo C1-8, donde el resto fenilo de fenoxi, fenoxialquilo, y fenilalquiloxi no se sustituye o se sustituye con amino, amino mono- di-sustituido con alquilo inferior C1-8, amido, sulfonamido, nitro, carboxilo o perfluoroalquilo C1-8; m es un numero entero de 0 a 6; Y se selecciona del grupo que consiste en hidrogeno, halogeno y alquilo inferior C1-8; n es un numero entero de 0 a 6; A es un grupo azol representado mediante la formula estructural (2) o (3) donde A1 se selecciona del grupo que consiste en un átomo de nitrogeno y CH; Q se selecciona del grupo que consiste en hidrogeno, perfluoroalquilo, halogeno, amino, alquilamino mono- o di-sustituido con alquilo inferior C1-8, amido, alquilo lineal o ramificado C1-8, cicloalquilo C3- 8, arilalquilo, morfolino, piperidino, pirrolidino, tioalcoxi C1-8, benciltio, tieinilo, aminoalquilo, hidroxialquilo, estirilo, carboxílico, piridinilo, fenilo no sustituido y fenilo sustituido con uno o más sustituyentes idénticos o diferentes seleccionados del grupo que consiste en hidrogeno, alquilo inferior C1-8, arilalquilo, halogeno, alcoxi C1-8, fenoxi, amino, amino mono- o di-sustituido con alquilo C1-8, nitro, hidroxi, tioalcoxi, furanilo, sulfonamido o perfluoroalquilo; R1 y R2 se seleccionan en forma independiente del grupo que consiste en hidrogeno, C(=O)NH2, alquilo inferior C1-8, fenilo no sustituido o sustituido, y fenilalquilo no sustituido o sustituido C1-8, o se toman junto con el nitrogeno al cual se encuentran unidos y forman un anillo imidazolico, de piperazina o fenil piperazina o un anillo de amina cíclica representado por la formula estructural (4), donde A2 se selecciona del grupo que consiste en un átomo de nitrogeno y un átomo de carbono; E y U se seleccionan en forma independiente del grupo que consiste en hidrogeno, hidroxi y O-carbamoilo o se toman juntos y forman oxo; W se selecciona de un anillo que consiste en piperonilo, indanilo, naftilo, tetrazolilo, triazolilo, piridilo y fenilo, anillo que puede sustituirse con uno o más sustituyentes idénticos o diferentes seleccionados del grupo que consiste en hidrogeno, alquilo inferior C1-8, halogeno, alcoxi C1-8, tioalcoxi C1-8, hidroxi, fenoxi, fenilalquiloxi C1-8, fenoxialquilo C1- 8, donde el resto fenilo de fenoxi, fenoxialquilo y fenilalquiloxi no se sustituye o se sustituye con amino, amono mono- o di-sustituido con alquilo C1-8, amido, sulfonamido, nitro, carboxilo, hidroxi o perfluoroalquilo C1-8; j es un numero entero de 0 a 4; y t es un numero entero de 0 a 4.
ARP060101598A 2005-04-22 2006-04-21 Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen AR053065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67453005P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR053065A1 true AR053065A1 (es) 2007-04-18

Family

ID=37115369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101598A AR053065A1 (es) 2005-04-22 2006-04-21 Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen

Country Status (21)

Country Link
US (1) US7598279B2 (es)
EP (1) EP1879873B1 (es)
JP (1) JP5035238B2 (es)
KR (1) KR101286499B1 (es)
CN (1) CN101228138B (es)
AR (1) AR053065A1 (es)
AU (1) AU2006237798B2 (es)
BR (1) BRPI0607529B8 (es)
CA (1) CA2606258C (es)
DK (1) DK1879873T3 (es)
ES (1) ES2441765T3 (es)
FI (1) FIC20210018I1 (es)
MX (1) MX2007013197A (es)
MY (1) MY148589A (es)
NL (1) NL301106I2 (es)
PL (1) PL1879873T3 (es)
PT (1) PT1879873E (es)
RU (1) RU2418792C2 (es)
TW (1) TWI398249B (es)
WO (1) WO2006112685A1 (es)
ZA (1) ZA200709994B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2686547C (en) * 2007-05-14 2015-12-08 Sk Holdings Co., Ltd. Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
JP5527668B2 (ja) * 2008-06-05 2014-06-18 エスケー バイオファーマスティカルズ カンパニー リミテッド ３−置換プロパンアミン化合物
BRPI0924997B1 (pt) * 2009-06-22 2024-01-16 Sk Biopharmaceuticals Co., Ltd Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
AU2013202982C1 (en) * 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ITUA20161941A1 (it) * 2016-03-23 2017-09-23 Univ Degli Studi Di Siena Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo
KR102421006B1 (ko) 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
CN110290788A (zh) * 2016-12-14 2019-09-27 爱思开生物制药株式会社 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
EP3556365A4 (en) * 2016-12-14 2020-06-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND FOR THE PREVENTION, RELIEF OR TREATMENT OF A DEMYLINATING DISEASE
WO2018111009A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2018111003A1 (ko) 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP7090616B2 (ja) * 2016-12-14 2022-06-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む口腔内崩壊錠
BR112019011914A2 (pt) * 2016-12-14 2019-11-05 Sk Biopharmaceuticals Co Ltd formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral.
CN111432814B (zh) * 2017-11-14 2024-05-14 爱思开生物制药株式会社 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
ES2973111T3 (es) 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
WO2019098633A1 (ko) 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도
WO2019098632A1 (ko) 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
CN111432813B (zh) 2017-11-14 2024-01-09 爱思开生物制药株式会社 用于预防、减轻、或治疗精神***症的包含氨基甲酸酯化合物的共混物
US20200352907A1 (en) * 2017-11-14 2020-11-12 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
MX2021003203A (es) 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
US10611737B1 (en) 2019-10-24 2020-04-07 Sk Biopharmaceuticals Co., Ltd. Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
KR20220104746A (ko) * 2019-11-22 2022-07-26 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 약제학적 조성물 및 그 제조방법
KR20230048032A (ko) 2020-08-06 2023-04-10 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 경구용 고형 제제 및 이의 제조방법
CN114317620B (zh) * 2020-09-29 2024-02-02 上海医药工业研究院 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法
CN115974799A (zh) * 2021-10-14 2023-04-18 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
ES2931000B2 (es) * 2022-07-14 2023-07-07 Univ Madrid Complutense Proceso para la preparación de cenobamato

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DK181988A (da) 1988-03-30 1989-10-01 Dumex Ltd As Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug
DE60222552T2 (de) * 2001-06-25 2008-06-26 Sk Corp. Carbamate von 2-heterozyklischen 1,2-ethandiolen
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds

Also Published As

Publication number Publication date
KR20080005437A (ko) 2008-01-11
ZA200709994B (en) 2008-11-26
TWI398249B (zh) 2013-06-11
EP1879873B1 (en) 2013-10-09
TW200722085A (en) 2007-06-16
CA2606258C (en) 2014-01-14
CA2606258A1 (en) 2006-10-26
BRPI0607529B8 (pt) 2021-05-25
KR101286499B1 (ko) 2013-07-16
EP1879873A1 (en) 2008-01-23
BRPI0607529A2 (pt) 2009-09-15
CN101228138A (zh) 2008-07-23
JP5035238B2 (ja) 2012-09-26
RU2418792C2 (ru) 2011-05-20
EP1879873A4 (en) 2011-06-15
US20060258718A1 (en) 2006-11-16
PL1879873T3 (pl) 2014-03-31
MY148589A (en) 2013-05-15
NL301106I2 (nl) 2021-08-03
ES2441765T3 (es) 2014-02-06
FIC20210018I1 (fi) 2021-06-14
CN101228138B (zh) 2012-11-21
DK1879873T3 (da) 2013-12-09
US7598279B2 (en) 2009-10-06
WO2006112685A1 (en) 2006-10-26
AU2006237798B2 (en) 2012-07-12
JP2008538557A (ja) 2008-10-30
RU2007143073A (ru) 2009-05-27
NL301106I1 (nl) 2021-06-02
PT1879873E (pt) 2014-01-03
AU2006237798A1 (en) 2006-10-26
BRPI0607529B1 (pt) 2021-05-18
MX2007013197A (es) 2008-02-12

Similar Documents

Publication Publication Date Title
AR053065A1 (es) Compuestos azolicos neuroterapeuticos y composiciones farmaceuticas que los contienen
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR072227A1 (es) Derivados de triazinona sustituidos
AR076098A1 (es) Derivados de benzofurano
AR073136A1 (es) Compuestos de pirrol
AR069526A1 (es) Compuesto heterociclico que contiene nitrogeno y su uso
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
ATE507205T1 (de) Aromatische 1,4-di-carboxylamide und deren verwendung
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
DK2010531T3 (da) Spirocykliske cyklohexanderivater med smertestillende virkning
HRP20050933A2 (en) Organic compounds
HRP20050543A2 (en) Substituted indolepyridinium as anti-infective compounds
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
PE20060626A1 (es) Aminas policiclicas sustituidas con arilo como antagonistas de mch1r
DOP2010000068A (es) Derivados de pirazol sustituidos
AR111466A1 (es) Inhibidores de hdac6 selectivos
ES2496592T3 (es) Proceso para la preparación de Imatinib y compuestos intermedios del mismo
MXPA05010816A (es) Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer.
RU2014145819A (ru) Бициклическое соединение
AR058698A1 (es) Carbonatos de fenicol con accion antibiotica y composicion farmaceutica
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
RU2010137115A (ru) Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов
BRPI1016232A2 (pt) Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol
AR057525A1 (es) Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
AR066242A1 (es) Tia(di)azoles como antagonistas del recpetor de dopamina 2 de disociacion rapida

Legal Events

Date Code Title Description
FG Grant, registration